Haematological malignancies are cancers that originate from lymphoid or myeloid cells and affect blood, bone marrow and lymph nodes. The tenth revision of the International Classification of Diseases (ICD-10) groups cases primarily by clinical presentation (leukaemia, myeloma or lymphoma). In contrast, the third edition of the International Classification of Diseases for Oncology (ICD-O-3) groups haematological malignancies primarily by cell lineage (lymphoid or myeloid), and includes some myeloid neoplasms that are not coded as malignant in ICD-10 ([@bib13]; [@bib37]). A hierarchical classification based on ICD-O-3 has been used in recent international collaborative studies ([@bib24]; [@bib32]; [@bib40]).

Alcohol drinking and tobacco smoking are modifiable exposures that are widespread in developed countries. Both are known to be associated with risks of certain types of haematological malignancy. Several recent cohort studies have reported decreasing trends in risk of non-Hodgkin lymphoma (NHL) and/or diffuse large B-cell lymphoma (a major subtype of NHL) with increasing alcohol intake among drinkers ([@bib18]; [@bib1]; [@bib14]; [@bib39]). Smoking is considered to be causally related to myeloid leukaemia in adults ([@bib12]), and (comparing current with never-smokers) has been associated with increased risk of Hodgkin lymphoma, acute myeloid leukaemia and myelodysplastic syndromes in recent cohort ([@bib8]; [@bib18]; [@bib27]; [@bib20], [@bib21]) and case--control ([@bib16]; [@bib2]) studies. However, haematological malignancies are probably heterogeneous in aetiology, and much of the evidence for subtype-specific associations remains inconclusive, perhaps reflecting inconsistent exposure classifications, or relatively small study sizes.

We examined association of subtypes of haematological malignancy with alcohol drinking and tobacco smoking in the prospective Million Women Study. To aid comparison with previous research, we report findings based on both ICD-O-3 and ICD-10. The large size of this cohort provides sufficient power to estimate risk for relatively rare subtypes.

Materials and methods
=====================

Definitions
-----------

The Million Women Study has been described elsewhere ([@bib31]). Between 1996 and 2001, with appropriate ethical approval, 1.3 million middle-aged women were recruited through breast cancer screening clinics in the United Kingdom. Participants gave written informed consent, and completed questionnaires recording personal and lifestyle characteristics (available at [www.millionwomenstudy.org](http://www.millionwomenstudy.org)). By linkage to the National Health Service Central Registers, participants are followed for death, emigration and cancer registration. Each incident neoplasm is coded using the combination of a disease code from ICD-10 and a morphology code from either the second or the third (ICD-O-3) edition of the International Classification of Diseases for Oncology.

For this analysis, haematological neoplasms were defined by the following ICD-10 codes: C81-C96 (malignant neoplasms of lymphoid, haematopoietic and related tissue), D45 (polycythemia vera), D46 (myelodysplastic syndromes) and D47 (other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue). Women were excluded if they had been diagnosed before recruitment with any haematological neoplasm (as defined above), or cancer of any other site except non-melanoma skin cancer (all other ICD-10 C codes except C44), or *in situ* breast carcinoma (ICD-10 D05), using equivalent definitions from earlier standard coding systems where necessary. For the remaining women, observation extended from the date of recruitment to the date of death, emigration, diagnosis with any of the neoplasms listed in the exclusion criteria, or end of follow-up, whichever occurred first. Follow-up ended on 31 December 2008 for Scotland and the North West (Merseyside and Cheshire) cancer registry region, and 31 December 2009 elsewhere.

Morphology codes for incident haematological neoplasms were converted from the second to the third edition as necessary ([@bib26]). Where the morphology code was uninformative (80001/80003, *N*=115) or discrepant (*N*=3), it was changed to match the ICD-10 code, unless both were non-specific (*N*=10). Malignant disease was defined and classified in two different ways ([Table 1](#tbl1){ref-type="table"}). ICD-O-3 morphology codes with fifth digit 3 (malignant) and first three digits in the range 959--998 (haematological neoplasms), except 975 (histiocytic and dendritic neoplasms, *N*=2), were grouped using a classification adapted from the InterLymph hierarchical scheme for epidemiological research ([@bib40]) and the Haemacare project ([@bib32]). Cases were grouped primarily by cell lineage. Subtypes of mature B-cell lymphoid malignancy included plasma cell neoplasms and 'CLL/SLL\' (cases coded as either chronic lymphocytic leukaemia or small lymphocytic lymphoma, now considered to be a single disease). Hodgkin lymphoma formed a separate subtype of lymphoid malignancy. Myeloid malignancies were divided into two subtypes: acute myeloid leukaemia and 'myeloproliferative/myelodysplastic disease\' (myeloproliferative and myelodysplastic neoplasms, including chronic myeloid leukaemia). For comparison, cases with ICD-10 codes C81-C96 were classified as Hodgkin lymphoma (C81), NHL (C82-C85, C96), 'myeloma\' (multiple myeloma, plasma cell neoplasms and malignant immunoproliferative diseases (C88, C90)) and leukaemia (C91-C95).

Statistical analysis
--------------------

Relative risk was estimated by Cox regression, taking attained age as the underlying time variable, and stratifying by cancer registry region of residence at recruitment (i.e. assuming equal coefficients across strata but with a baseline hazard unique to each stratum) ([@bib35]). The proportional hazards assumption was examined using Schoenfeld residuals and found acceptable. To assess the possibility that associations might reflect lifestyle changes caused by subclinical disease (reverse causation), all analyses were repeated without the first 3 years of follow-up. All statistical tests were two-sided and used the 5% significance level.

Categorical exposure measures were derived from information given on the questionnaire completed by each woman at the time of recruitment to the study, as follows: current weekly alcohol consumption (none, 0.5--\<3, 3--\<7, ⩾7 drinks, in units equivalent to approximately 10 g of pure alcohol); tobacco smoking (past, never, current \<15 cigarettes per day, current ⩾15 cigarettes per day); socioeconomic status (within-study quintiles of the 1991 Townsend deprivation index for the census enumeration district or output area containing the woman\'s home address at recruitment ([@bib38])); body mass index (\<25, 25--\<30, ⩾30 kg m^−2^); height (\<160, 160--\<165, ⩾165 cm). The questions relevant to smoking habits were 'About how many cigarettes do you smoke on average each day, now?\' and 'Are you an ex-smoker?\' (yes/no). Body mass index ([@bib31]) and height ([@bib11]) were known to be associated with risks of haematological malignancy in this cohort.

In turn, each of the two factors of interest (alcohol and smoking) was treated as the main explanatory variable, with all the other exposure measures acting as adjustment factors. Women with missing information for the explanatory variable were excluded from that analysis; those with missing information for an adjustment factor were included as a separate category of the adjustment factor. Trends were assessed by allocating a score to each category of the explanatory variable, and fitting log-linear models to the change in hazard ratio per unit increase in score. Current non-drinkers were excluded from the alcohol trend model, and ex-smokers from the smoking trend model, because reasons for abstention might include ill-health. As an approximate correction for regression dilution bias ([@bib22]), each category of drinking and smoking was scored as the mean daily intake reported at re-survey approximately 3 years after recruitment among women in that category: drinks in units of approximately 10 g pure alcohol per day (0.26, 0.75, 1.63) and smoking in multiples of 10 cigarettes per day (0, 1.10, 2.00), scoring self-reported never-smokers at recruitment as zero. Heterogeneity of trends between diagnostic groups was assessed by a *χ*^2^ contrast test ([@bib34]).

Results
=======

Descriptive statistics
----------------------

The number of women who were eligible for these analyses was 1 319 121, after excluding 45 035 with neoplasms diagnosed before recruitment. On average, women were aged 56.6 years at recruitment, and contributed 10.3 person-years to the analyses.

The number of women diagnosed with haematological malignancies during follow-up was 9162 according to the hierarchical classification based on ICD-O-3, and 7941 according to the simple ICD-10 grouping ([Table 1](#tbl1){ref-type="table"}); the main reason for the difference was that clinical behaviour for 1230 cases of myeloproliferative/myelodysplastic disease was treated as malignant in ICD-O-3 but uncertain or unknown in ICD-10. Of the 5093 mature B-cell cases, 2679 (53%) were coded in ICD-10 as NHL, 1597 (31%) as myeloma and 817 (16%) as leukaemia.

Information on alcohol consumption at recruitment was obtained from 1 308 786 women (99%), of whom 994 030 (76%) reported ⩾0.5 drinks per week ([Table 2](#tbl2){ref-type="table"}). Among drinkers at recruitment, the mean intake reported at re-survey was 5.6 drinks per week, a moderate level by national standards ([@bib29]). Of the 1 241 605 women (94%) who could be classified as never, current or past smokers at recruitment, 21% (255 148) were current smokers and 28% (352 493) were past smokers. The measure of socioeconomic status was available for 1 309 534 women (99%). Height was reported by 98% of women, and both height and weight (enabling calculation of body mass index) by 95%.

Socioeconomic status, body mass index, height and age varied with alcohol and tobacco intake ([Table 2](#tbl2){ref-type="table"}). The proportion of participants with relatively low socioeconomic status was smaller for drinkers than non-drinkers, and greater for current smokers than never-smokers. On average, drinkers were slightly leaner, taller and younger than non-drinkers, and current smokers were slightly leaner, shorter and younger than never-smokers.

Alcohol
-------

Using the ICD-O-3 classification, and taking occasional drinkers (0.5--\<3 drinks per week) as the reference group, the estimated relative risk of haematological malignancy was 0.90 (95% confidence interval 0.85--0.95) for ⩾7 drinks per week ([Table 3](#tbl3){ref-type="table"}). Among drinkers, there was a statistically significant decreasing trend with increasing alcohol intake (*P*~trend~\<0.001; [Table 3](#tbl3){ref-type="table"}); the estimated relative risk for an increase of 10 g per day was 0.92 (0.89--0.96) ([Figure 1](#fig1){ref-type="fig"}). In more detail, there was a statistically significant decreasing trend for the lymphoid subgroup (*P*~trend~\<0.001) and no apparent trend for the myeloid subgroup, although the test for heterogeneity between lymphoid and myeloid trends was not statistically significant (*P*~het~=0.09; [Figure 1](#fig1){ref-type="fig"}). Among specified subtypes of lymphoid malignancy, there was a statistically significant trend only for mature B-cell disease (*P*~trend~\<0.001), within which there were similar significant decreasing trends for diffuse large B-cell lymphoma, follicular lymphoma and plasma cell neoplasms, but not CLL/SLL; the test for heterogeneity was not statistically significant (*P*~het~=0.1). For Hodgkin lymphoma, the risk was significantly higher in non-drinkers than in occasional drinkers (relative risk 1.70 (1.27--2.26); [Table 3](#tbl3){ref-type="table"}); a similar result was obtained when the first 3 years of follow-up were excluded (data not shown).

Using the ICD-10 classification, there were significant decreasing trends for NHL and myeloma separately, and little evidence of association for leukaemia or Hodgkin lymphoma, although the test for heterogeneity of trends between diagnostic groups was not statistically significant (*P*~het~=0.06) ([Figure 1](#fig1){ref-type="fig"}).

Excluding the first 3 years of follow-up made little difference to the trend estimates, but changed results from non-significant to significant for the tests of heterogeneity between lymphoid and myeloid malignancies (*P*~het~=0.01) and between mature B-cell subtypes (*P*~het~=0.01) (Table 5).

Smoking
-------

Using the ICD-O-3 classification, and taking women who had never smoked as the reference group, the estimated relative risk of haematological malignancy for frequent smokers (⩾15 cigarettes per day) was 1.30 (1.20--1.40) ([Table 4](#tbl4){ref-type="table"}). There were statistically significant trends in both lymphoid (1.07 (1.03--1.12)) and myeloid (1.33 (1.24--1.42)) disease, with strong evidence of heterogeneity between these groups (*P*~het~\<0.001) ([Figure 1](#fig1){ref-type="fig"}). There was also strong evidence of heterogeneity within lymphoid disease (*P*~het~\<0.001), with statistically significant increasing trends for Hodgkin lymphoma (1.45 (1.22--1.72)) and mature T-cell malignancies (1.38 (1.10--1.73)) but not for mature B-cell malignancies. There was heterogeneity between subgroups of myeloid malignancy (*P*~het~=0.001), with a statistically significant trend for myeloproliferative/myelodysplastic disease (1.42 (1.31--1.55)) but not for acute myeloid leukaemia (1.10 (0.96--1.26)). Comparing frequent smokers with never-smokers, the estimated relative risks of Hodgkin lymphoma, mature T-cell malignancies and myeloproliferative/myelodysplastic disease were each approximately doubled (2.19 (1.56--3.09), 2.09 (1.33--3.26) and 1.98 (1.67--2.35), respectively) ([Table 4](#tbl4){ref-type="table"}).

Using the ICD-10 classification, there was strong evidence of heterogeneity between subgroups (*P*~het~\<0.001), with statistically significant increasing trends for Hodgkin lymphoma and NHL but not for myeloma or leukaemia ([Figure 1](#fig1){ref-type="fig"}).

Excluding the first 3 years of follow-up made little difference to the trend estimates, and did not affect the conclusions of the tests for heterogeneity ([Table 5](#tbl5){ref-type="table"}).

Discussion
==========

Alcohol
-------

In this cohort, most women who drank alcohol were moderate drinkers. Among the drinkers, greater alcohol intake was associated with significantly reduced risks of diffuse large B-cell lymphoma, follicular lymphoma and plasma cell neoplasms, lymphoid and mature B-cell disease overall, but not other specified lymphoid subtypes or myeloid malignancies. Although there was no statistically significant heterogeneity between subtypes in the main analysis, significant heterogeneity between lymphoid and myeloid malignancies, and between mature B-cell subtypes, emerged when the first 3 years of follow-up were excluded. Thus some of the apparent lack of heterogeneity might be due to reverse causation. Using the ICD-10 classification, there were significant inverse associations with risks of NHL and myeloma, but not leukaemia or Hodgkin lymphoma.

Previous cohort studies have reported a statistically significant decreasing trend with greater alcohol intake among drinkers for diffuse large B-cell lymphoma ([@bib18]; [@bib39]), and no significant trend for Hodgkin lymphoma, follicular lymphoma, plasma cell neoplasms or any other non-Hodgkin subtype examined ([@bib18]; [@bib14]; [@bib39]), although one study found a near-significant decreasing trend for plasma cell neoplasms ([@bib39]); comparable results from case--control studies were generally consistent with these findings ([@bib25]; [@bib2], [@bib3]). In studies that estimated risks in drinkers relative to non-drinkers, similar results were obtained for lymphoid subtypes ([@bib15]; [@bib4]) except for one observation of increased CLL/SLL risk in drinkers ([@bib4]), and there was no trend in risk of acute myeloid leukaemia ([@bib21]) or myelodysplastic syndromes ([@bib20]). A multi-centre case--control study reported lower risk of Hodgkin lymphoma in ever-regular drinkers compared with never-regular drinkers, based on 222 cases ([@bib2]). In our study, with 281 cases in total, the risk of Hodgkin lymphoma was estimated to be lower among current occasional drinkers (at recruitment) than in current non-drinkers, but there was no significant trend in risk with increasing intake; excluding the first 3 years of follow-up did not change either of these findings.

Using a similar ICD-10 classification, an earlier analysis of data from the Million Women Study with 7.2 years of follow-up on average ([@bib1]) reported a statistically significant inverse association in drinkers for NHL, but not for myeloma or leukaemia; the significant association with myeloma seen in the analysis reported here probably reflects the larger number of cases accumulated over a longer follow-up period. These results are broadly consistent with comparable findings from other cohort ([@bib5]; [@bib17]) and case--control ([@bib9], [@bib10]) studies.

Our findings strengthen existing evidence for an association of greater alcohol intake with reduced risk of diffuse large B-cell lymphoma among drinkers, and demonstrate similar associations for two further subtypes of lymphoid disease: follicular lymphoma and plasma cell neoplasms. Further work is needed to elucidate potential biological mechanisms; for example, the role of chronic inflammation ([@bib33]; [@bib4]).

Smoking
-------

We found statistically significant increasing trends in risk of Hodgkin lymphoma, mature T-cell malignancies and myeloproliferative/myelodysplastic disease with increasing current cigarette consumption relative to never-smokers (approximately double risk for women who reported smoking ⩾15 cigarettes per day), but no significant trends for mature B-cell malignancy or any of its subtypes. Tests for heterogeneity between diagnostic subgroups were highly significant. The trend estimate for acute myeloid leukaemia, although above unity, was not statistically significant. Using the ICD-10 classification, there were significant increasing trends for Hodgkin lymphoma and NHL but not for myeloma or leukaemia. Excluding the first 3 years of follow-up did not affect these conclusions.

Recent cohort studies, also comparing current smokers with never-smokers, have reported statistically significant associations for Hodgkin lymphoma ([@bib18]; [@bib27]), myelodysplastic syndromes ([@bib20]) and acute myeloid leukaemia ([@bib8]; [@bib21]), but no association for T-cell malignancies or any other non-Hodgkin subtype examined ([@bib18]; [@bib27]; [@bib39]; [@bib19]). Results from case--control studies were similar: comparing current with never-smokers there were significant positive associations for Hodgkin lymphoma ([@bib2]) and acute myeloid leukaemia ([@bib16]), but no association for T-cell malignancies or any other non-Hodgkin subtype examined ([@bib23]; [@bib3]) except for one positive association for follicular lymphoma ([@bib23]); comparing ever- with never-smokers there were significant positive associations for myelodysplastic syndromes ([@bib28]; [@bib36]). Trend analyses including former smokers suggested (in a cohort study) an inverse association with follicular lymphoma ([@bib18]) and (in a case--control study) a positive association with Hodgkin lymphoma ([@bib15]).

Our findings support existing evidence for associations of smoking with Hodgkin lymphoma and myelodysplastic syndromes (a subset of myeloproliferative/myelodysplastic disease), and demonstrate a similar association for mature T-cell malignancies. Tobacco smoke contains benzene and other known leukaemogens, and it has been concluded that there is 'sufficient evidence in humans\' that tobacco smoking causes myeloid (but not lymphoid) leukaemia ([@bib12]). Hence, smoking is a plausible cause of myeloproliferative/myelodysplastic disease, which includes chronic myeloid leukaemia and various myeloid pre-leukaemic conditions. An association with T-cell disease has not been reported before, to our knowledge, perhaps because this is a relatively rare diagnostic group. It has been suggested that smoking might impair the T-cell-mediated immune response to Epstein--Barr virus infection, a putative causal factor for Hodgkin lymphoma ([@bib27]), and it is tempting to speculate that such a process might also promote T-cell malignancies.

Strengths and limitations
-------------------------

This very large prospective study clarifies and extends existing evidence for associations of subtypes of haematological malignancy with alcohol and tobacco consumption, using two different current classification systems. Exposures were reported by the study participants at recruitment, and follow-up for death, emigration and cancer registration was virtually complete. Estimates were mutually adjusted for alcohol and smoking, socioeconomic status, body mass index and height. Reverse causation is an unlikely explanation for the associations seen, as excluding the first 3 years of follow-up did not qualitatively change the results.

Although the analysis was stratified by cancer registry region of residence at recruitment, variation in diagnostic and coding practice remains a possible source of bias. The registries adopted ICD-O-3 during the study period, at times that differed between regions, and previous ascertainment of myeloproliferative/myelodysplastic disease is likely to have been incomplete ([@bib30]). Subclassification of lymphoma may sometimes have been inaccurate ([@bib6], [@bib7]) and was often imprecise. Conceivably, time to diagnosis might be associated with the factors of interest: for example, causes of mediastinal symptoms of Hodgkin lymphoma might perhaps be investigated more rapidly in smokers because of the well-known risk of lung disease in smokers. However, the strong and highly significant associations reported are unlikely to be due to coding problems, or to chance.

Conclusions
===========

Relative risks associated with alcohol and tobacco consumption among middle-aged women in the United Kingdom were estimated for subtypes of haematological malignancy. Among predominantly moderate drinkers, greater alcohol intake was associated with reduced risk of lymphoid malignancies: in particular, diffuse large B-cell lymphoma, consistent with previous reports, and follicular lymphoma and plasma cell neoplasms (not previously reported, to our knowledge). Cigarette smoking was associated with increased risk of Hodgkin lymphoma, consistent with previous reports, mature T-cell malignancies (not previously reported, to our knowledge) and myeloproliferative/myelodysplastic disease (previously reported for myelodysplastic syndromes, but not for the grouping used here).
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###### Number of women diagnosed with haematological neoplasms during follow-up: cross-classification by ICD-O-3 and ICD-10

  **Classification**              **ICD-O-3**                                                      **ICD-10**                                                                               
  ------------------------------- ---------------------------------------------------------------- ------------ --------------------- ---------------- ------------------ ----------------- -----------
  **Term**                        **All specified codes have 5th digit 3 (malignant behaviour)**   **HL C81**   **NHL C82-C85 C96**   **MMC88, C90**   **Leuk C91-C95**   **Oth D45-D47**   **Total**
  *Lymphoid malignancies*         *959--973, 976, 982--983, 9940, 9948*                            *287*        *4226*                *1597*           *937*              *0*               *7047*
   Hodgkin lymphoma               965--966                                                         287          0                     0                0                  0                 287
   Mature B cell                  967--969 except (9675), 973, 976, 9823, 9826, 9833, 9940                                                                                                   
    Diffuse large B cell            9678, 9679, 9680, 9684                                         0            1151                  1                0                  0                 1152
    Follicular lymphoma             969 except 9699                                                0            1027                  0                0                  0                 1027
    Plasma cell neoplasms           973                                                            0            0                     1518             0                  0                 1518
    CLL/SLL                         9670, 9823                                                     0            133                   0                787                0                 920
    Other/unspec. mat. B cell       9671, 9673, 9687, 9689, 9699, 976, 9826, 9833, 9940            0            368                   78               30                 0                 476
   Mature T cell                  970--971, 9827, 9831, 9834, 9948                                 0            194                   0                3                  0                 197
   Other/unspec. lymphoid         959, 9675, 972, 9820, 983 except (9831, 9833, 9834)              0            1353                  0                117                0                 1470
                                                                                                                                                                                             
  *Myeloid malignancies*          *974, 984--998 except (9940, 9948)*                              *0*          *8*                   *0*              *831*              *1233*            *2072*
   Acute myeloid leukaemia        984--993 except (9860, 9863, 9875, 9876), 9984                   0            0                     0                614                3                 617
   Myeloprolif./dysplastic dis.   974, 9863, 9875, 9876, 9945, 9946, 995--998 except 9984          0            8                     0                192                1230              1430
   Other/unspec. myeloid          9860                                                             0            0                     0                25                 0                 25
                                                                                                                                                                                             
  *Unspecified lineage*           *980*                                                            *0*          *0*                   *0*              *43*               *0*               *43*
                                                                                                                                                                                             
  *Not haematological cancer*     *800, 975, any code with 5th digit not 3*                        *0*          *12*                  *0*              *0*                *243*             *255*
  All haematological neoplasms                                                                     287          4246                  1597             1811               1476              9417

Abbreviations: CLL/SLL=chronic lymphocytic leukaemia/small lymphocytic lymphoma; HL=Hodgkin lymphoma; ICD-O-3=International Classification of Diseases for Oncology 3rd edition; ICD-10=International Classification of Diseases 10th revision; Leuk=leukaemia; MM=myeloma (multiple myeloma, plasma cell neoplasms and malignant immunoproliferative diseases); Myeloprolif./dysplastic dis.=myeloproliferative/myelodysplastic disease (including chronic myeloid leukaemia); NHL=non-Hodgkin lymphoma; Oth=other haematological neoplasms.

###### Characteristics of the women included in these analyses

                                                             **Alcohol**   **Smoking**                                             
  ---------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  Number of women                                            314 756       994 030       352 493       633 964       255 148       1 319 121
                                                                                                                                    
  *Characteristics at recruitment*                                                                                                  
   % Drinkers[a](#t2-fn2){ref-type="fn"}                     --            --            81            76            70            76
   % Current smokers                                         26            19            --            --            --            21
   % Lower socioeconomic status[b](#t2-fn3){ref-type="fn"}   45            30            33            27            48            33
   Body mass index (kg m^−2^): mean (s.d.)                   27.2 (5.4)    25.9 (4.4)    26.7 (4.8)    26.2 (4.6)    25.6 (4.5)    26.2 (4.7)
   Height (cm): mean (s.d.)                                  161.2 (6.9)   162.2 (6.7)   162.3 (6.7)   162.0 (6.7)   161.5 (6.8)   162.0 (6.7)
   Age (years): mean (s.d.)                                  57.3 (4.9)    56.4 (4.8)    56.8 (4.9)    56.8 (4.9)    55.8 (4.5)    56.6 (4.9)
                                                                                                                                    
  *Follow-up*                                                                                                                       
   Woman-years observed (1000s)                              3218.0        10270.0       3622.3        6608.7        2562.9        13593.7
   Number of incident cases: ICD-O--3                        2469          6617          2532          4312          1797          9162
   Number of incident cases: ICD-10                          2152          5726          2191          3808          1487          7941

Abbreviations: ICD-O-3=International Classification of Diseases for Oncology 3rd edition; ICD-10=International Classification of Diseases 10th revision.

⩾0.5 drinks per week, in units equivalent to 10 g pure alcohol.

Highest within-study tertile of the 1991 Townsend deprivation index for the census enumeration district or output area of the home address.

###### Association of alcohol drinking with risk of haematological malignancies

                                                                    **All women**   **Non-drinkers**   **0.5--\<3 drinks per week**   **3--\<7 drinks per week**   **⩾7 drinks per week**   **Trend among drinkers**                                                                
  ----------------------------------------------------------------- --------------- ------------------ ------------------------------ ---------------------------- ------------------------ -------------------------- ------ ------ ------------ ------ ------ ------------ ------ ---------
  *All haematological malignancies*                                                                                                                                                                                                                                                 
   ICD-O-3 classification                                           9086            2469               1.05                           0.99, 1.10                   3364                     1.00                       1384   0.91   0.85, 0.96   1869   0.90   0.85, 0.95   6617   \<0.001
   ICD-10 classification                                            7878            2152               1.06                           1.00, 1.12                   2924                     1.00                       1201   0.90   0.84, 0.96   1601   0.89   0.83, 0.94   5726   \<0.001
                                                                                                                                                                                                                                                                                     
  *Subgroups of ICD-O-3 classification*                                                                                                                                                                                                                                             
   ICD-O-3 haematological malignancies[b](#t3-fn4){ref-type="fn"}                                                                                                                                                                                                                    
    Lymphoid                                                        6990            1912               1.06                           1.00, 1.12                   2602                     1.00                       1067   0.90   0.84, 0.97   1409   0.88   0.82, 0.94   5078   \<0.001
    Myeloid                                                         2053            546                1.01                           0.91, 1.14                   745                      1.00                       311    0.93   0.81, 1.06   451    0.99   0.88, 1.11   1507   0.8
   ICD-O-3 lymphoid malignancies                                                                                                                                                                                                                                                     
    Hodgkin lymphoma                                                281             108                1.70                           1.27, 2.26                   85                       1.00                       31     0.79   0.53, 1.20   57     1.06   0.76, 1.49   173    0.6
    Mature B cell                                                   5056            1344               1.01                           0.94, 1.08                   1925                     1.00                       763    0.87   0.80, 0.95   1024   0.87   0.81, 0.94   3712   \<0.001
    Mature T cell                                                   196             40                 0.78                           0.53, 1.15                   71                       1.00                       35     1.04   0.70, 1.57   50     1.05   0.73, 1.52   156    0.7
    Other/unspecified lymphoid                                      1457            420                1.18                           1.03, 1.34                   521                      1.00                       238    1.00   0.85, 1.16   278    0.84   0.73, 0.98   1037   0.02
   ICD-O-3 mature B-cell malignancies                                                                                                                                                                                                                                                
    Diffuse large B-cell lymphoma                                   1145            331                1.07                           0.93, 1.24                   443                      1.00                       153    0.77   0.64, 0.92   218    0.82   0.69, 0.96   814    0.01
    Follicular lymphoma                                             1021            255                0.96                           0.82, 1.13                   389                      1.00                       171    0.94   0.78, 1.13   206    0.82   0.69, 0.98   766    0.02
    Plasma cell neoplasms                                           1506            406                1.00                           0.88, 1.14                   587                      1.00                       223    0.84   0.72, 0.98   290    0.82   0.71, 0.95   1100   0.006
    CLL/SLL                                                         911             245                1.10                           0.93, 1.30                   327                      1.00                       148    1.00   0.82, 1.22   191    0.97   0.81, 1.16   666    0.6
    Other/unspecified mature B-cell                                 473             107                0.83                           0.65, 1.06                   179                      1.00                       68     0.84   0.64, 1.12   119    1.11   0.88, 1.40   366    0.4
   ICD-O-3 myeloid malignancies[c](#t3-fn5){ref-type="fn"}                                                                                                                                                                                                                           
    Acute myeloid leukaemia                                         613             165                0.99                           0.81, 1.21                   233                      1.00                       89     0.84   0.66, 1.08   126    0.89   0.71, 1.11   448    0.3
    Myeloproliferative/myelodysplastic disease                      1415            372                1.02                           0.89, 1.17                   503                      1.00                       220    0.98   0.83, 1.15   320    1.03   0.89, 1.19   1043   0.7
                                                                                                                                                                                                                                                                                     
  *Subgroups of ICD-10 classification*                                                                                                                                                                                                                                              
   ICD-10 haematological malignancies                                                                                                                                                                                                                                                
    Hodgkin lymphoma                                                281             108                1.70                           1.27, 2.26                   85                       1.00                       31     0.79   0.53, 1.20   57     1.06   0.76, 1.49   173    0.6
    Non-Hodgkin lymphoma                                            4216            1132               1.02                           0.95, 1.11                   1593                     1.00                       652    0.89   0.82, 0.98   839    0.84   0.77, 0.92   3084   \<0.001
    Myeloma                                                         1584            422                0.99                           0.88, 1.13                   616                      1.00                       231    0.83   0.72, 0.97   315    0.85   0.74, 0.98   1162   0.02
    Leukaemia                                                       1797            490                1.12                           0.99, 1.26                   630                      1.00                       287    1.01   0.87, 1.16   390    1.01   0.89, 1.15   1307   0.9

Abbreviations: Cases=number of incident cases; CI=confidence interval; CLL/SLL=chronic lymphocytic leukaemia/small lymphocytic lymphoma; ICD-O-3=International Classification of Diseases for Oncology 3rd edition; ICD-10=International Classification of Diseases 10th revision; *P*~trend~=result of test for categorical trend per 10 g per day; Ref=referent; RR=relative risk.

Myeloproliferative/myelodysplastic disease includes chronic myeloid leukaemia.

Reported alcohol consumption at recruitment, in units of approximately 10 g pure alcohol. RR estimates are adjusted for body mass index, height, smoking and socioeconomic status, and stratified by cancer registry region. Follow-up starts at recruitment.

Excludes 43 unspecified cases.

Excludes 25 other/unspecified cases.

###### Association of tobacco smoking with risk of haematological malignancies

                                                                     **All women**   **Ex-smokers**   **Never-smokers**   **\<15 cigarettes per day**   **≥15 cigarettes per day**   **Trend among never- or current smokers**                                                             
  ----------------------------------------------------------------- --------------- ---------------- ------------------- ----------------------------- ---------------------------- ------------------------------------------- ----- ------ ------------ ----- ------ ------------ ------ ---------
  *All haematological malignancies*                                                                                                                                                                                                                                                        
   ICD-O-3 classification                                                8641             2532              1.09                  1.04, 1.15                       4312                                1.00                      896   1.13   1.05, 1.22   901   1.30   1.20, 1.40   6109   \<0.001
   ICD-10 classification                                                 7486             2191              1.07                  1.01, 1.13                       3808                                1.00                      747   1.06   0.98, 1.15   740   1.19   1.10, 1.29   5295   \<0.001
                                                                                                                                                                                                                                                                                                
  *Subgroups of ICD-O-3 classification*                                                                                                                                                                                                                                                         
   ICD-O-3 haematological malignancies[b](#t4-fn4){ref-type="fn"}                                                                                                                                                                                                                               
    Lymphoid                                                             6638             1938              1.06                  1.01, 1.13                       3394                                1.00                      653   1.04   0.96, 1.14   653   1.18   1.09, 1.29   4700   \<0.001
    Myeloid                                                              1963             582               1.19                  1.07, 1.32                       902                                 1.00                      238   1.46   1.26, 1.69   241   1.69   1.46, 1.96   1381   \<0.001
   ICD-O-3 lymphoid malignancies                                                                                                                                                                                                                                                                
    Hodgkin lymphoma                                                      263              60               0.90                  0.66, 1.23                       122                                 1.00                      31    1.30   0.87, 1.94   50    2.19   1.56, 3.09   203    \<0.001
    Mature B cell                                                        4803             1427              1.07                  1.00, 1.14                       2498                                1.00                      452   0.98   0.89, 1.09   426   1.06   0.96, 1.18   3376     0.5
    Mature T cell                                                         184              61               1.38                  0.98, 1.93                        78                                 1.00                      17    1.15   0.68, 1.95   28    2.09   1.33, 3.26   123     0.006
    Other/unspecified lymphoid                                           1388             390               1.05                  0.93, 1.19                       696                                 1.00                      153   1.20   1.01, 1.44   149   1.31   1.10, 1.58   998     0.001
   ICD-O-3 mature B-cell malignancies                                                                                                                                                                                                                                                           
    Diffuse large B-cell lymphoma                                        1084             332               1.11                  0.96, 1.27                       560                                 1.00                      99    0.97   0.78, 1.21   93    1.04   0.83, 1.30   752      0.7
    Follicular lymphoma                                                   976             283               1.07                  0.92, 1.24                       497                                 1.00                      94    1.00   0.80, 1.25   102   1.22   0.98, 1.52   693      0.1
    Plasma cell neoplasms                                                1425             428               1.08                  0.96, 1.22                       750                                 1.00                      140   1.03   0.86, 1.24   107   0.91   0.74, 1.12   997      0.4
    CLL/SLL                                                               870             252               1.02                  0.87, 1.19                       461                                 1.00                      84    1.00   0.79, 1.26   73    1.01   0.78, 1.29   618      0.9
    Other/unspecified mature B cell                                       448             132               1.02                  0.82, 1.27                       230                                 1.00                      35    0.79   0.55, 1.13   51    1.32   0.96, 1.80   316      0.3
   ICD-O-3 myeloid malignancies[c](#t4-fn5){ref-type="fn"}                                                                                                                                                                                                                                      
    Acute myeloid leukaemia                                               586             172               1.08                  0.89, 1.31                       291                                 1.00                      70    1.29   0.99, 1.68   53    1.08   0.80, 1.46   414      0.2
    Myeloproliferative/myelodysplastic disease                           1353             404               1.24                  1.09, 1.41                       602                                 1.00                      163   1.52   1.27, 1.81   184   1.98   1.67, 2.35   949    \<0.001
                                                                                                                                                                                                                                                                                                
  *Subgroups of ICD-10 classification*                                                                                                                                                                                                                                                     
   ICD-10 haematological malignancies                                                                                                                                                                                                                                                           
    Hodgkin lymphoma                                                      263              60               0.90                  0.66, 1.23                       122                                 1.00                      31    1.30   0.87, 1.94   50    2.19   1.56, 3.09   203    \<0.001
    Non-Hodgkin lymphoma                                                 4011             1176              1.08                  1.01, 1.16                       2024                                1.00                      392   1.05   0.94, 1.17   419   1.26   1.14, 1.41   2835   \<0.001
    Myeloma                                                              1496             450               1.08                  0.96, 1.21                       789                                 1.00                      144   1.01   0.84, 1.21   113   0.92   0.75, 1.12   1046     0.3
    Leukaemia                                                            1716             505               1.06                  0.95, 1.19                       873                                 1.00                      180   1.12   0.95, 1.32   158   1.11   0.93, 1.32   1211     0.1

Abbreviations: Cases=number of incident cases; CI=confidence interval; CLL/SLL=chronic lymphocytic leukaemia/small lymphocytic lymphoma; ICD-O-3=International Classification of Diseases for Oncology 3rd edition; ICD-10=International Classification of Diseases 10th revision; *P*~trend~=result of test for categorical trend per 10 cigarettes per day; Ref=referent; RR=relative risk.

Myeloproliferative/myelodysplastic disease includes chronic myeloid leukaemia.

Reported smoking habit at recruitment. RR estimates are adjusted for body mass index, height, alcohol consumption and socioeconomic status, and stratified by cancer registry region. Follow-up starts at recruitment.

Excludes 40 unspecified cases.

Excludes 24 other/unspecified cases.

###### Association of alcohol drinking and tobacco smoking with risk of haematological malignancies: trend analysis excluding the first 3 years of follow-up

                                                                      **Alcohol**   **Smoking**                                                         
  ----------------------------------------------------------------- --------------- ----------------- ------------ --------- ------ ------ ------------ ---------
  *All haematological malignancies*                                                                                                                     
   ICD-O-3 classification                                                5235       0.94              0.89, 0.98   0.006      4825  1.14   1.09, 1.18   \<0.001
   ICD-10 classification                                                 4528       0.92              0.87, 0.97   0.001      4170  1.07   1.03, 1.12   0.001
                                                                                                                                                         
  *Subgroups of ICD-O-3 classification*                                                                                                                 
   ICD-O-3 haematological malignancies[c](#t5-fn5){ref-type="fn"}    *P*~het~=0.01  *P*~het~\<0.001                                                     
    Lymphoid                                                             4031       0.91              0.86, 0.96   \<0.001    3721  1.07   1.02, 1.12   0.006
    Myeloid                                                              1177       1.04              0.95, 1.15   0.4        1082  1.36   1.26, 1.47   \<0.001
   ICD-O-3 lymphoid malignancies                                     *P*~het~=0.2   *P*~het~\<0.001                                                     
    Hodgkin lymphoma                                                      129       1.07              0.79, 1.44   0.7        152   1.57   1.29, 1.90   \<0.001
    Mature B cell                                                        3045       0.90              0.84, 0.95   \<0.001    2774  1.00   0.95, 1.06   0.9
    Mature T cell                                                         118       1.19              0.88, 1.61   0.3         88   1.34   1.02, 1.77   0.03
    Other/unspecified lymphoid                                            739       0.88              0.78, 1.00   0.05       707   1.17   1.06, 1.30   0.002
   ICD-O-3 mature B-cell malignancies                                *P*~het~=0.01  *P*~het~=0.2                                                        
    Diffuse large B-cell lymphoma                                         699       0.83              0.72, 0.95   0.005      650   1.03   0.92, 1.16   0.6
    Follicular lymphoma                                                   590       0.88              0.76, 1.02   0.08       542   1.08   0.96, 1.22   0.2
    Plasma cell neoplasms                                                 901       0.83              0.74, 0.94   0.002      820   0.92   0.83, 1.02   0.1
    CLL/SLL                                                               540       0.97              0.83, 1.12   0.6        494   0.96   0.84, 1.10   0.6
    Other/unspecified mature B cell                                       315       1.19              0.99, 1.43   0.07       268   1.10   0.93, 1.30   0.3
   ICD-O-3 myeloid malignancies[c](#t5-fn5){ref-type="fn"}           *P*~het~=0.4   *P*~het~\<0.001                                                     
    Acute myeloid leukaemia                                               343       0.98              0.81, 1.17   0.8        311   1.07   0.91, 1.26   0.4
    Myeloproliferative/myelodysplastic disease                            821       1.07              0.95, 1.21   0.2        759   1.48   1.35, 1.62   \<0.001
                                                                                                                                                         
  *Subgroups of ICD-10 classification*                                                                                                                   
   ICD-10 haematological malignancies                                *P*~het~=0.06  *P*~het~\<0.001                                                     
    Hodgkin lymphoma                                                      129       1.07              0.79, 1.44   0.7        152   1.57   1.29, 1.90   \<0.001
    Non-Hodgkin lymphoma                                                 2435       0.89              0.83, 0.96   0.001      2227  1.12   1.05, 1.18   \<0.001
    Myeloma                                                               947       0.86              0.76, 0.96   0.008      856   0.92   0.83, 1.02   0.1
    Leukaemia                                                            1017       1.03              0.93, 1.14   0.6        935   1.03   0.94, 1.13   0.5

Abbreviations: Cases, number of incident cases; CI, confidence interval; CLL/SLL, chronic lymphocytic leukaemia/small lymphocytic lymphoma; ICD-O-3, International Classification of Diseases for Oncology 3rd edition; ICD-10, International Classification of Diseases 10th revision; *P*~het~ result of *χ*^2^ contrast test for heterogeneity of trends between subtypes; Ref, referent; *P*~trend,~ result of test for categorical trend; RR, relative risk.

Myeloproliferative/myelodysplastic disease includes chronic myeloid leukaemia.

Relative risk per 10 g per day, adjusted for body mass index, height, smoking and socioeconomic status, and stratified by cancer registry region.

Relative risk per 10 cigarettes per day, adjusted for body mass index, height, alcohol consumption and socioeconomic status, and stratified by cancer registry region.

Excludes other/unspecified cases.
